Exact Mass: 491.3108
Exact Mass Matches: 491.3108
Found 402 metabolites which its exact mass value is equals to given mass value 491.3108
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
DB-065692
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents
Bardoxolone
C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent > C2198 - Nonnarcotic Analgesic C471 - Enzyme Inhibitor > C29574 - Nitric Oxide Synthase Inhibitor C471 - Enzyme Inhibitor > C1323 - Cyclooxygenase Inhibitor
N-Docosahexaenoyl Tyrosine
N-docosahexaenoyl tyrosine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Docosahexaenoyl amide of Tyrosine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Docosahexaenoyl Tyrosine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Docosahexaenoyl Tyrosine is therefore classified as a very long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.
Bardoxolone
Epothilone D
Lidoflazine
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C - Cardiovascular system > C08 - Calcium channel blockers > C08E - Non-selective calcium channel blockers D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
3,9,14,15alpha,16beta,20-Hexahydroxy-A-nor-5beta-cevan-3alpha-carbonsaeure-9-lacton|3,9,14,15alpha,16beta,20-hexahydroxy-A-nor-5beta-cevane-3alpha-carboxylic acid-9-lactone
(3R)-3-hydroxy-12-{(1S,4S)-4-[(1S)-1-hydroxyethyl]-pyrrolidin-1-yl}-dodecanoic acid-3-O-beta-D-glucopyranoside|morusimic acid A
(2S,3Z)-5-{[(2R,3R,5S,6S)-6-{(2E,4E)-5-[(3R,5S,7S)-7-hydroxy-7-methyl-1,6-dioxaspiro[2.5]oct-5-yl]-3-methylpenta-2,4-dien-1-yl}-2,5-dimethyltetrahydro-2H-pyran-3-yl]amino}-5-oxopent-3-en-2-yl acetate
3beta-hydroxy-(22E,24R)-ergosta-5,8(14),22-triene-1,2-dicarboxylic acid imide|ergosterimide
Ala Phe Arg Val
Ala Phe Val Arg
Ala Arg Phe Val
Ala Arg Val Phe
Ala Val Phe Arg
Ala Val Arg Phe
Phe Ala Arg Val
Phe Ala Val Arg
Phe Gly Ile Arg
Phe Gly Leu Arg
Phe Gly Arg Ile
Phe Gly Arg Leu
Phe Ile Gly Arg
Phe Ile Asn Val
Phe Ile Arg Gly
Phe Ile Val Asn
Phe Lys Pro Thr
Phe Lys Thr Pro
Phe Lys Val Val
Phe Leu Gly Arg
Phe Leu Asn Val
Phe Leu Arg Gly
Phe Leu Val Asn
Phe Asn Ile Val
Phe Asn Leu Val
Phe Asn Val Ile
Phe Asn Val Leu
Phe Pro Lys Thr
Phe Pro Thr Lys
Phe Gln Val Val
Phe Arg Ala Val
Phe Arg Gly Ile
Phe Arg Gly Leu
Phe Arg Ile Gly
Phe Arg Leu Gly
Phe Arg Val Ala
Phe Thr Lys Pro
Phe Thr Pro Lys
Phe Val Ala Arg
Phe Val Ile Asn
Phe Val Lys Val
Phe Val Leu Asn
Phe Val Asn Ile
Phe Val Asn Leu
Phe Val Gln Val
Phe Val Arg Ala
Phe Val Val Lys
Phe Val Val Gln
Gly Phe Ile Arg
Gly Phe Leu Arg
Gly Phe Arg Ile
Gly Phe Arg Leu
Gly Ile Phe Arg
Gly Ile Arg Phe
Gly Leu Phe Arg
Gly Leu Arg Phe
Gly Arg Phe Ile
Gly Arg Phe Leu
Gly Arg Ile Phe
Gly Arg Leu Phe
Ile Phe Gly Arg
Ile Phe Asn Val
Ile Phe Arg Gly
Ile Phe Val Asn
Ile Gly Phe Arg
Ile Gly Arg Phe
Ile Lys Met Thr
Ile Lys Thr Met
Ile Met Lys Thr
Ile Met Thr Lys
Ile Asn Phe Val
Ile Asn Val Phe
Ile Arg Phe Gly
Ile Arg Gly Phe
Ile Thr Lys Met
Ile Thr Met Lys
Ile Val Phe Asn
Ile Val Asn Phe
Lys Phe Pro Thr
Lys Phe Thr Pro
Lys Phe Val Val
Lys Ile Met Thr
Lys Ile Thr Met
Lys Leu Met Thr
Lys Leu Thr Met
Lys Met Ile Thr
Lys Met Leu Thr
Lys Met Thr Ile
Lys Met Thr Leu
Lys Pro Phe Thr
Lys Pro Thr Phe
Lys Thr Phe Pro
Lys Thr Ile Met
Lys Thr Leu Met
Lys Thr Met Ile
Lys Thr Met Leu
Lys Thr Pro Phe
Lys Val Phe Val
Lys Val Val Phe
Leu Phe Gly Arg
Leu Phe Asn Val
Leu Phe Arg Gly
Leu Phe Val Asn
Leu Gly Phe Arg
Leu Gly Arg Phe
Leu Lys Met Thr
Leu Lys Thr Met
Leu Met Lys Thr
Leu Met Thr Lys
Leu Asn Phe Val
Leu Asn Val Phe
Leu Arg Phe Gly
Leu Arg Gly Phe
Leu Thr Lys Met
Leu Thr Met Lys
Leu Val Phe Asn
Leu Val Asn Phe
Met Ile Lys Thr
Met Ile Thr Lys
Met Lys Ile Thr
Met Lys Leu Thr
Met Lys Thr Ile
Met Lys Thr Leu
Met Leu Lys Thr
Met Leu Thr Lys
Met Thr Ile Lys
Met Thr Lys Ile
Met Thr Lys Leu
Met Thr Leu Lys
Asn Phe Ile Val
Asn Phe Leu Val
Asn Phe Val Ile
Asn Phe Val Leu
Asn Ile Phe Val
Asn Ile Val Phe
Asn Leu Phe Val
Asn Leu Val Phe
Asn Val Phe Ile
Asn Val Phe Leu
Asn Val Ile Phe
Asn Val Leu Phe
Pro Phe Lys Thr
Pro Phe Thr Lys
Pro Lys Phe Thr
Pro Lys Thr Phe
Pro Thr Phe Lys
Pro Thr Lys Phe
Gln Phe Val Val
Gln Val Phe Val
Gln Val Val Phe
Arg Ala Phe Val
Arg Ala Val Phe
Arg Phe Ala Val
Arg Phe Gly Ile
Arg Phe Gly Leu
Arg Phe Ile Gly
Arg Phe Leu Gly
Arg Phe Val Ala
Arg Gly Phe Ile
Arg Gly Phe Leu
Arg Gly Ile Phe
Arg Gly Leu Phe
Arg Ile Phe Gly
Arg Ile Gly Phe
Arg Leu Phe Gly
Arg Leu Gly Phe
Arg Val Ala Phe
Arg Val Phe Ala
Thr Phe Lys Pro
Thr Phe Pro Lys
Thr Ile Lys Met
Thr Ile Met Lys
Thr Lys Phe Pro
Thr Lys Ile Met
Thr Lys Leu Met
Thr Lys Met Ile
Thr Lys Met Leu
Thr Lys Pro Phe
Thr Leu Lys Met
Thr Leu Met Lys
Thr Met Ile Lys
Thr Met Lys Ile
Thr Met Lys Leu
Thr Met Leu Lys
Thr Pro Phe Lys
Thr Pro Lys Phe
Val Ala Phe Arg
Val Ala Arg Phe
Val Phe Ala Arg
Val Phe Ile Asn
Val Phe Lys Val
Val Phe Leu Asn
Val Phe Asn Ile
Val Phe Asn Leu
Val Phe Gln Val
Val Phe Arg Ala
Val Phe Val Lys
Val Phe Val Gln
Val Ile Phe Asn
Val Ile Asn Phe
Val Lys Phe Val
Val Lys Val Phe
Val Leu Phe Asn
Val Leu Asn Phe
Val Asn Phe Ile
Val Asn Phe Leu
Val Asn Ile Phe
Val Asn Leu Phe
Val Gln Phe Val
Val Gln Val Phe
Val Arg Ala Phe
Val Arg Phe Ala
Val Val Phe Lys
Val Val Phe Gln
Val Val Lys Phe
Val Val Gln Phe
(5R,11R,13S,14S,17S)-11-[4-(Dimethylamino)phenyl]-13-methyl-17-(1 -propyn-1-yl)-1,2,6,7,8,11,12,13,14,15,16,17-dodecahydrospiro[cyc lopenta[a]phenanthrene-3,2-[1,3]dioxolane]-5,17(4H)-diol
2,2,5,5-Tetramethyl-1-((11-(Triethoxysilyl)Undecyl)Oxy)-1,2,5-Azadisilolidine
Lidoflazine
C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C - Cardiovascular system > C08 - Calcium channel blockers > C08E - Non-selective calcium channel blockers D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
(1R,2S,4R,5R,8R,9S,11S)-2-[[(2R,3S,4S,5S,6R)-3,4-dihydroxy-5-methoxy-6-methyloxan-2-yl]oxymethyl]-9-formyl-5-methyl-13-propan-2-yltetracyclo[7.4.0.02,11.04,8]tridec-12-ene-1-carboxylate
(13E)-4,8-dihydroxy-5,5,7,9,13-pentamethyl-16-[(E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-1-oxacyclohexadec-13-ene-2,6-dione
3-[4-[(8R,9R,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
1-[(4R,7R,8R)-5-[2-(dimethylamino)-1-oxoethyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(4S,7S,8R)-5-[2-(dimethylamino)-1-oxoethyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(4S,7S,8S)-5-[2-(dimethylamino)-1-oxoethyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
(5S,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
(5S,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
(4R,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4R,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4S,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
3-[4-[(8R,9R,10S)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(8S,9S,10S)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(8S,9R,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
4-[4-[(8R,9S,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propan-2-yl-2-(3-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
(2R)-2-[(4S,5S)-5-[[cyclopentylmethyl(methyl)amino]methyl]-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
[(1S)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-(4-oxanylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
1-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-9-[[oxo-(propan-2-ylamino)methyl]amino]-2,3,4,7-tetrahydro-1,5-benzoxazonin-2-yl]methyl]-1-methyl-3-propan-2-ylurea
(2S)-2-[(4R,5R)-5-[[cyclopentylmethyl(methyl)amino]methyl]-8-[3-(dimethylamino)prop-1-ynyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol
1-[(4S,7R,8R)-5-[2-(dimethylamino)-1-oxoethyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(4R,7R,8S)-5-[2-(dimethylamino)-1-oxoethyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(4R,7S,8R)-5-[2-(dimethylamino)-1-oxoethyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
1-[(4R,7S,8S)-5-[2-(dimethylamino)-1-oxoethyl]-8-methoxy-4,7,10-trimethyl-11-oxo-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-propan-2-ylurea
(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
(5S,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-8-carboxamide
(4S,7S,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4S,7R,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4S,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4R,7R,8S)-8-methoxy-4,7,10-trimethyl-11-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
(4R,7S,8R)-8-methoxy-4,7,10-trimethyl-11-oxo-14-[[oxo-(propan-2-ylamino)methyl]amino]-N-propan-2-yl-2-oxa-5,10-diazabicyclo[10.4.0]hexadeca-1(12),13,15-triene-5-carboxamide
3-[4-[(8S,9S,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(8R,9S,10R)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(8R,9S,10S)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
3-[4-[(8S,9R,10S)-10-(hydroxymethyl)-6-(4-oxanylmethyl)-1,6-diazabicyclo[6.2.0]decan-9-yl]phenyl]-N,N-dimethylbenzamide
(1S)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-2-(2-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propyl-2-(2-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
[(1R)-7-methoxy-2-[(3-methoxyphenyl)methyl]-1-(4-oxanylmethyl)-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,3-azetidine]yl]methanol
(1R)-1-(hydroxymethyl)-7-methoxy-9-methyl-N-propan-2-yl-2-(3-pyridinylmethyl)-1-spiro[1,3-dihydropyrido[3,4-b]indole-4,4-piperidine]carboxamide
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
2-aminoethyl [2-hydroxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propyl] hydrogen phosphate
[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-hydroxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (9Z,12Z)-nonadeca-9,12-dienoate
(E)-3-hydroxy-2-(2-hydroxydodecanoylamino)tridec-4-ene-1-sulfonic acid
3-hydroxy-2-[[(Z)-2-hydroxytetradec-9-enoyl]amino]undecane-1-sulfonic acid
(E)-3-hydroxy-2-(2-hydroxytridecanoylamino)dodec-4-ene-1-sulfonic acid
3-hydroxy-2-[[(Z)-2-hydroxytridec-8-enoyl]amino]dodecane-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] acetate
3-hydroxy-2-[[(Z)-2-hydroxydodec-5-enoyl]amino]tridecane-1-sulfonic acid
3-hydroxy-2-[[(Z)-2-hydroxypentadec-9-enoyl]amino]decane-1-sulfonic acid
(E)-3-hydroxy-2-(2-hydroxytetradecanoylamino)undec-4-ene-1-sulfonic acid
(E)-3-hydroxy-2-(2-hydroxypentadecanoylamino)dec-4-ene-1-sulfonic acid
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] propanoate
[1-acetyloxy-3-[2-aminoethoxy(hydroxy)phosphoryl]oxypropan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
2-[2,3-Di(trimethylsilyloxy)butoxy]-N-[2-(dimethylamino)ethyl]-4-quinolinecarboxamide
2-[[(4E,8E)-2-(heptanoylamino)-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(butanoylamino)-3-hydroxypentadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-acetamido-3-hydroxyheptadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(pentanoylamino)tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[hydroxy-[(4E,8E)-3-hydroxy-2-(propanoylamino)hexadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
2-[[(4E,8E)-2-(hexanoylamino)-3-hydroxytrideca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
Epothilone D
An epithilone that is epithilone C in which the hydrogen at position 13 of the oxacyclohexadec-13-ene-2,6-dione macrocycle has been replaced by a methyl group. C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent D050258 - Mitosis Modulators > D050256 - Antimitotic Agents > D050257 - Tubulin Modulators D000970 - Antineoplastic Agents > D050256 - Antimitotic Agents
phosphatidylethanolamine 18:2 zwitterion
A 1,2-diacyl-sn-glycero-3-phosphoethanolamine zwitterion in which the two acyl groups contain a total of 18 carbons and 2 double bonds.
lysophosphatidylcholine 16:2
A lysophosphatidylcholine in which the remaining acyl group contains 16 carbons and 2 double bonds. If R1 is the acyl group and R2 is a hydrogen then the molecule is a 1-acyl-sn-glycero-3-phosphocholine. If R1 is a hydrogen and R2 is the acyl group then the molecule is a 2-acyl-sn-glycero-3-phosphocholine.
N-docosenoylsphingosine-1-phosphocholine
A sphingomyelin in which the total number of carbons in the fatty acyl group is 22 with 1 double bond.
PE(18:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
PC(15:2)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved